Utrophin luciferase knock-in mouse model for in vivo assessment of drug efficacy in preclinical trials for utrophin upregulation by Fairclough, R, Davies, K

Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches. by Fairclough, R, Wood, M, Davies, K

Progress in therapy for Duchenne muscular dystrophy. by Fairclough, R, Bareja, A, Davies, K

Progress in therapy for Duchenne muscular dystrophy by Fairclough, R, Bareja, A, Davies, K

Pharmacologically targeting the primary defect and downstream pathology in Duchenne muscular dystrophy. by Fairclough, R, Perkins, K, Davies, K

TREAT-NMD-Activity 7: Accelerate preclinical phase of new therapeutic treatment development by Willmann, R, Rueegg, M, Fairclough, R, Davies, K, Possekel, S, Meier, T

Assessing the effects of exercise-induced stress on the Fiona mouse model by Bareja, A, Fairclough, R, Potter, A, Powell, D, Squire, S, Davies, K

Future clinical and biomarker development for SMTC1100, the first utrophin modulator to enter clinical trials for Duchenne Muscular Dystrophy (DMD) by Tinsley, J, Robinson, N, Wilson, F, Horne, G, Fairclough, R, Davies, K

Utrophin upregulation in DMD therapy: current status and new tools for the future by Fairclough, R, Powell, D, Squire, S, Potter, A, Bareja, A, Russell, A, Davies, S, Davies, K

Evaluation of novel compounds for upregulation of utrophin in animal models of Duchenne muscular dystrophy therapy by Fairclough, R, Potter, A, Powell, D, Squire, S, Bland, M, Bareja, A, Tinsley, J, Davies, K

Functional comparison of wild type human secretory pathway Ca2+/Mn2+ ATPase with Hailey Hailey disease mutants by Fairclough, R, Dode, L, Vanocvelen, J, Monaco, A, Missiaen, L, Raeymaekers, L, Wuytack, F, Hovnanian, A

Identification of new chemical compounds with upregulate utrophin for the therapy of Duchenne muscular dystrophy by Fairclough, R, Squire, SE, Potter, A, Powell, D, Davies, S, Bataille, C, Wynne, G, Russell, A, Davies, K

Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin. by Li, D, Bareja, A, Judge, L, Yue, Y, Lai, Y, Fairclough, R, Davies, K, Chamberlain, J, Duan, D

Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin by Li, D, Bareja, A, Judge, L, Yue, Y, Lai, Y, Fairclough, R, Davies, K, Chamberlain, J, Duan, D

Hailey-Hailey disease: molecular and clinical characterization of novel mutations in the ATP2C1 gene. by Dobson-Stone, C, Fairclough, R, Dunne, E, Brown, J, Dissanayake, M, Munro, C, Strachan, T, Burge, S, Sudbrak, R, Monaco, A, Hovnanian, A

Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. by Tinsley, J, Fairclough, R, Storer, R, Wilkes, F, Potter, A, Squire, SE, Powell, D, Cozzoli, A, Capogrosso, R, Lambert, A, Wilson, F, Wren, S, De Luca, A, Davies, K

New orally available compounds which modulate utrophin expression for the therapy of Duchenne muscular dystrophy (DMD) by Fairclough, R, Guiraud, S, Squire, SE, Babbs, A, Edward, B, Shah, N, Bracchi, A, Wilson, F, Horne, G, Robinson, N, Araujo, N, Hewings, D, Vuorinen, A, Davies, S, Wynne, G, Russell, A, Tinsley, J, Davies, K

Gata3-deficient mice develop parathyroid abnormalities due to dysregulation of the parathyroid-specific transcription factor Gcm2. by Grigorieva, I, Mirczuk, S, Gaynor, K, Nesbit, M, Grigorieva, E, Wei, Q, Ali, A, Fairclough, R, Stacey, J, Stechman, M, Mihai, R, Kurek, D, Fraser, W, Hough, T, Condie, BG, Manley, N, Grosveld, F, Thakker, R